Mostrar el registro sencillo

dc.contributor.authorGarcía Gutiérrez, Lucía
dc.contributor.authorDelgado Villar, María Dolores 
dc.contributor.authorLeón Serrano, Javier 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2019-10-08T07:51:31Z
dc.date.available2019-10-08T07:51:31Z
dc.date.issued2019
dc.identifier.issn2073-4425
dc.identifier.otherSAF2017-88026-Res_ES
dc.identifier.urihttp://hdl.handle.net/10902/16972
dc.description.abstractPromotion of the cell cycle is a major oncogenic mechanism of the oncogene c-MYC (MYC). MYC promotes the cell cycle by not only activating or inducing cyclins and CDKs but also through the downregulation or the impairment of the activity of a set of proteins that act as cell-cycle brakes. This review is focused on the role of MYC as a cell-cycle brake releaser i.e., how MYC stimulates the cell cycle mainly through the functional inactivation of cell cycle inhibitors. MYC antagonizes the activities and/or the expression levels of p15, ARF, p21, and p27. The mechanism involved differs for each protein. p15 (encoded by CDKN2B) and p21 (CDKN1A) are repressed by MYC at the transcriptional level. In contrast, MYC activates ARF, which contributes to the apoptosis induced by high MYC levels. At least in some cells types, MYC inhibits the transcription of the p27 gene (CDKN1B) but also enhances p27's degradation through the upregulation of components of ubiquitin ligases complexes. The effect of MYC on cell-cycle brakes also opens the possibility of antitumoral therapies based on synthetic lethal interactions involving MYC and CDKs, for which a series of inhibitors are being developed and tested in clinical trials.es_ES
dc.description.sponsorshipThe work in the laboratory of the authors is funded by grant SAF2017-88026-R from MINECO, Spanish Government, to J.L. and M.D.D., L.G.-G. was recipient of a fellowship from the FPI program from MINECO. The funding was co-sponsored by FEDER program from European Uniones_ES
dc.format.extent29 p.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rights© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) 4.0 licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceGenes, 2019, 10(3), 244es_ES
dc.subject.otherMYCes_ES
dc.subject.otherCell cyclees_ES
dc.subject.otherCDK inhibitorses_ES
dc.subject.otherp21es_ES
dc.subject.otherp27es_ES
dc.subject.otherp15es_ES
dc.subject.otherARFes_ES
dc.titleMYC oncogene contributions to release of cell cycle brakeses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://www.doi.org/10.3390/genes10030244es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.3390/genes10030244
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) 4.0 licenseExcepto si se señala otra cosa, la licencia del ítem se describe como © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) 4.0 license